Genocea Biosciences Inc. buy stratec
Summary
This prediction ended on 06.09.18 with a price of €4.33. Massive losses of -51.60% were the result for the BUY prediction by stratec. stratec has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | 1.164% | 1.549% | 24.351% | 23.659% |
iShares Nasdaq 100 | 0.118% | 0.969% | 28.865% | 41.786% |
iShares Nikkei 225® | 1.124% | -1.120% | 17.443% | 6.454% |
iShares S&P 500 | 0.479% | 1.068% | 28.585% | 42.511% |
Comments by stratec for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Genocea : Cantor sees five-bagger potential
Cantor Fitzgerald set a Street-high price target of $5, suggesting a near-quintupling from today's close of $1.03.